State of Alaska Department of Revenue Boosts Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

State of Alaska Department of Revenue increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 26.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,716 shares of the company’s stock after purchasing an additional 4,526 shares during the period. State of Alaska Department of Revenue’s holdings in Harmony Biosciences were worth $747,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its position in Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after buying an additional 351,582 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after buying an additional 140,690 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Harmony Biosciences by 68.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after acquiring an additional 93,622 shares during the last quarter. Citigroup Inc. boosted its holdings in Harmony Biosciences by 9.8% during the 3rd quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock valued at $7,114,000 after acquiring an additional 15,859 shares during the period. Finally, HealthInvest Partners AB grew its position in Harmony Biosciences by 335.2% during the 3rd quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after acquiring an additional 116,975 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeffrey Dierks sold 1,123 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 over the last 90 days. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Down 0.3 %

NASDAQ:HRMY opened at $38.98 on Friday. The company has a 50 day simple moving average of $36.06 and a two-hundred day simple moving average of $35.60. The company has a market cap of $2.22 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61.

Analyst Ratings Changes

HRMY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday. They set a “buy” rating and a $55.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a report on Monday, January 27th. Finally, Cantor Fitzgerald boosted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences presently has a consensus rating of “Buy” and a consensus price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.